p-Hydroxy-5,6-dehydrokawainCAS# 39986-86-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 39986-86-2 | SDF | Download SDF |
| PubChem ID | 10243535 | Appearance | Powder |
| Formula | C14H12O4 | M.Wt | 244.2 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 6-[(E)-2-(4-hydroxyphenyl)ethenyl]-4-methoxypyran-2-one | ||
| SMILES | COC1=CC(=O)OC(=C1)C=CC2=CC=C(C=C2)O | ||
| Standard InChIKey | VWYHYOYHRIWSJU-QPJJXVBHSA-N | ||
| Standard InChI | InChI=1S/C14H12O4/c1-17-13-8-12(18-14(16)9-13)7-4-10-2-5-11(15)6-3-10/h2-9,15H,1H3/b7-4+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 4'-Hydroxy-5,6-dehydrokawain shows significant antiproliferative activity against murine colon 26-L5 carcinoma. |
| In vitro | Six new diarylheptanoids from the seeds of Alpinia blepharocalyx.[Reference: WebLink]Journal of Natural Products, 2001, 64(3):289-293.
|
p-Hydroxy-5,6-dehydrokawain Dilution Calculator
p-Hydroxy-5,6-dehydrokawain Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.095 mL | 20.475 mL | 40.95 mL | 81.9001 mL | 102.3751 mL |
| 5 mM | 0.819 mL | 4.095 mL | 8.19 mL | 16.38 mL | 20.475 mL |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.095 mL | 8.19 mL | 10.2375 mL |
| 50 mM | 0.0819 mL | 0.4095 mL | 0.819 mL | 1.638 mL | 2.0475 mL |
| 100 mM | 0.041 mL | 0.2048 mL | 0.4095 mL | 0.819 mL | 1.0238 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Delta-9-Tetrahydrocannabivarinic acid
Catalog No.:BCN7967
CAS No.:39986-26-0
- HOAt
Catalog No.:BCC2815
CAS No.:39968-33-7
- Victoxinine
Catalog No.:BCN6745
CAS No.:39965-06-5
- LY 78335
Catalog No.:BCC6109
CAS No.:39959-66-5
- Norglaucine hydrochloride
Catalog No.:BCN6568
CAS No.:39945-41-0
- 2'-Deoxycytidine hydrochloride
Catalog No.:BCC5434
CAS No.:3992-42-5
- 29-Hydroxyfriedelan-3-one
Catalog No.:BCN5453
CAS No.:39903-21-4
- H-D-Phe(4-OMe)-OH
Catalog No.:BCC2633
CAS No.:39878-65-4
- PHA-680632
Catalog No.:BCC2178
CAS No.:398493-79-3
- JNJ 5207852 dihydrochloride
Catalog No.:BCC6101
CAS No.:398473-34-2
- 19-Hydroxybufalin
Catalog No.:BCN8237
CAS No.:39844-86-5
- Methyllinderone
Catalog No.:BCN5452
CAS No.:3984-73-4
- Laricitrin 3-O-glucoside
Catalog No.:BCN8149
CAS No.:39986-90-8
- H-Thr-OMe.HCl
Catalog No.:BCC3104
CAS No.:39994-75-7
- 24, 25-Dihydroxy VD3
Catalog No.:BCC1303
CAS No.:40013-87-4
- Syringetin-3-O-glucoside
Catalog No.:BCN2610
CAS No.:40039-49-4
- SU 3327
Catalog No.:BCC7725
CAS No.:40045-50-9
- N6-Benzoyladenine
Catalog No.:BCC9075
CAS No.:4005-49-6
- 20-Hydroxyganoderic acid G
Catalog No.:BCN8231
CAS No.:400604-12-8
- Ceftaroline fosamil
Catalog No.:BCC5266
CAS No.:400827-46-5
- H-Arg-pNA.2HCl
Catalog No.:BCC2858
CAS No.:40127-11-5
- Erucifoline
Catalog No.:BCN2081
CAS No.:40158-95-0
- Boc-N-Me-Phe.DCHA
Catalog No.:BCC3348
CAS No.:40163-88-0
- SKA 31
Catalog No.:BCC7743
CAS No.:40172-65-4
Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms.[Pubmed:28427810]
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2401-2406.
An imbalance between bone resorption by osteoclasts and bone formation by osteoblasts can cause bone loss and bone-related disease. In a previous search for natural products that increase osteogenic activity, we found that 5,6-dehydrokawain (1) from Alpinia zerumbet promotes osteoblastogenesis. In this study, we synthesized and evaluated series of 5,6-dehydrokawain analogs. Our structure-activity relationships revealed that alkylation of para or meta position of aromatic ring of 1 promote osteogenic activity. Among the potential analogs we synthesized, (E)-6-(4-Ethylstyryl)-4-methoxy-2H-pyran-2-one (14) and (E)-6-(4-Butylstyryl)-4-methoxy-2H-pyran-2-one (21) both significantly up-regulated Runx2 and Osterix mRNA expression at 10microM. These osteogenic activities could be mediated by bone morphogenetic protein (BMP) and activation of p38 MAPK signaling pathways. Compounds 14 and 21 also inhibited RANKL-induced osteoclast differentiation of RAW264 cells. These results indicated that novel 5,6-dehydrokawain analogs not only increase osteogenic activity but also inhibit osteoclast differentiation, and could be potential lead compounds for the development of anti-osteoporosis agents.
Syntheses and biological activities of dihydro-5,6-dehydrokawain derivatives.[Pubmed:8987662]
Biosci Biotechnol Biochem. 1996 Oct;60(10):1643-5.
The syntheses and biological activities of dihydro-5,6-dehydrokawain derivatives against plant pathogenic fungi and termites were investigated. Dihydro-5,6-dehydrokawain was isolated by a simple method without chromatography from the leaves of Alpinia speciosa K. SCHUM. The white crystalline compound obtained was identified as dihydro-5,6-dehydrokawain (1) by instrumental analyses. 4-Hydroxy-6-(2-phenylethyl)-2H-pyran-2-one (3) was prepared by hydrolyzing dihydro-5,6-dehydrokawain. Three dihydro-5,6-dehydrokawain derivatives were synthesized by reacting 3 with phosphoric agents. Among the synthesized compounds, dimethyl [6-(2-phenylethyl)-2-oxo-2H-pyran-4-yl]phosphorothionate (4) had the strongest antifungal activity of 91% at 100 ppm against Corticium rolfsii.
5,6-Dehydrokawain from Alpinia zerumbet promotes osteoblastic MC3T3-E1 cell differentiation.[Pubmed:26940726]
Biosci Biotechnol Biochem. 2016 Jul;80(7):1425-32.
Bone homeostasis is maintained by balancing bone formation and bone resorption, but an imbalance between them is associated with various bone-related diseases such as osteoporosis and rheumatoid arthritis. We found that 5,6-dehydrokawain (DK) and dihydro-5,6-dehydrokawain (DDK), which were isolated as promising compounds from Alpinia zerumbet rhizomes, promote differentiation of osteoblastic MC3T3-E1 cells. DK and DDK increased the alkaline phosphatase activity and matrix mineralization of MC3T3-E1 cells. DK exerts larger effects than DDK. The gene expression of runt-related transcription factor 2 and osterix, which are essential transcription factors in the early period of osteoblast differentiation, was significantly increased by DK treatment. The mRNA level of distal-less homeobox 5 was also enhanced by DK treatment, and DK activated the p38 mitogen-activated protein kinase pathway. Therefore, DK may have clinical potential for preventing osteoporosis, and could be considered as a potential anabolic therapeutic agent.
